Highlights from ACR Convergence’s Late-Breaking Abstracts

References

1. Singh J, Singh N, Anzalone A, et al. Breakthrough COVID-19 infections post-vaccination among immunocompromised patients with autoimmune or inflammatory rheumatic diseases: A retrospective cohort analysis from a U.S. nationally sampled electronic medical record data repository [abstract L16]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
2. Deepak P, Kim W, Paley MA, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2. Ann Intern Med. 2021 Nov;174(11):1572–1585.
3. Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 Sep;80(9):1137–1146.
4. Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021 Oct;80(10):1345–1350.
5. Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: A randomized controlled trial [abstract L17]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
6. Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immune responses to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: A cohort study [abstract L18]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
7. Venhoff N, Schmidt W, Bergner R, et al. Secukinumab in giant cell arteritis: A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial [abstract L19]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
8. de Benedetti F, Grom A, Brogan P, et al. Efficacy of emapalumab, an anti-IFNγ antibody in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) who had failed high-dose glucocorticoids (GCs) [abstract L20]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
9. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020 May 7;382(19):1811–1822.
10. Terrier B, Pugnet G, de Moreuil C, et al. Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: A double-blind, randomized, controlled trial [abstract L21]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
11. Terrier B, Darbon R, Durel CA, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis. 2020 Dec 29;15(suppl 2):351.
12. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366–1383.